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toms. Among patients managed by office-based physicians (n753), oral antibiot-
ics and aminosalicylates (72% and 68% of patients, respectively) were the common
treatments. Among those managed by hospital-based physicians (n756), amin-
osalicylates were infrequently prescribed (11% of patients) and intravenous anti-
biotics were preferred over oral (67% and 36%, respectively). Fifty-seven percent of
patients were hospitalized, with the majority being for acute disease management
or diagnostics. Among those hospitalized, mean [SD] length of stay was 12.6 [31.8]
days. CONCLUSIONS: Diverticulitis presents a significant disease burden to health
care systems and patients in Europe. Many patients with diverticulitis present with
or develop serious complications, leading to frequent hospitalization and long hos-
pital stays.
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Spontaneous reporting of adverse drug reactions (ADRs) by health care staff using
the respective ADR reporting forms plays the key role in the Pharmacovigilance
system of various countries. Under-reporting of ADRs is a serious public health
issue. Occurrence of ADR varies from people to people and country to country. In
any given country, the ADR reporting form holds the key to collect vital ADR related
information. But, the structure and content of this form vary widely from country
to country.OBJECTIVES:The present study involved the collection and comparison
of ADR reporting forms of 55 different countries. METHODS: We analyzed the
uniformity of the forms by identifying 25 critical reporting parameters that assure
drug safety and ensure the casualty relationship between the drug and the ADR.
The non-English forms were translated using Google Translate. RESULTS: It re-
vealed through our study that only 8 out of 55 countries (14.5%) had at least 75% of
the parameters covered in their form. The ADR reporting form of Ukraine was
found to have 20 parameters (80%) covered. Following that, the ADR reporting
forms of India, Republic of China, and Malaysia covered 19 parameters (76%). Many
countries lack vital information about the patient. CONCLUSIONS: This study has
helped to identify the lack of information. There should be internationally recog-
nized uniform guidelines and checklists for designing of spontaneous reporting
forms. Though there are differences between the countries in gathering informa-
tion about suspected ADRs, the drug safety data from each country ultimately goes
to one single database – Vigibase. The reporting system and the forms used in most
of the developing nations should be improved, which in turn improves the quality
use of medicines in the respective country.
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OBJECTIVES: 1) To determine whether the use of duloxetine during pregnancy is
associated with an increased risk for major malformations; 2) examine rates of
spontaneous abortions(SA), therapeutic abortions(TA), stillbirths, as well as mean
birth-weight and gestational age at delivery; and 3) examine rates of Poor Neonatal
Adaptation Syndrome (PNAS) following late pregnancy exposure. METHODS: Data
was collected from either women or their health care providers who had requested
information regarding the use of duloxetine during pregnancy. The study design
was prospective, with two comparison groups, 1) exposed to other antidepressants,
and 2) exposed to non-teratogens (NTC). RESULTS: We completed 624 pregnancy
outcomes which included 208 in each group. Rates of major malformations were
similar across groups (p0.992). Significant differences were noted only in rates of
spontaneous abortions (p0.011) and admissions to neonatal intensive care unit/
special care nursery (p0.010). There were more preterm births in the duloxetine
group, although the results were not statistically different. There were 3/53 (5.6%)
cases consistent with PNAS symptoms in the duloxetine group with no evidence of
a dose response.CONCLUSIONS:Duloxetine does not appear to increase the rate of
major malformations above baseline. The higher rate of SA corroborates similar
results from other studies of antidepressant use in pregnancy. The incidence of
symptoms of PNAS in our study is somewhat lower than in prior studies reporting
on this outcome. These data add to the information regarding SNRI use in preg-
nancy, which will enable a woman, together with her physician, to make an evi-
dence-based decision regarding the use of duloxetine.
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OBJECTIVES: The University of Michigan Women’s Registry database contains in-
formation on 2,771 women. In addition to menopause diagnoses, the database
contains demographic characteristic, body mass index (BMI), menopause symp-
tom, hormone therapy, surgery, and other comorbidity information. This study
aims to compare the demographic and clinical characteristics between women
diagnosed with menopause versus those who were not, and explore the relation-
ship between menopause symptoms and diagnosis. METHODS: Demographic and
clinical characteristics between women diagnosed with menopause and those who
were not were compared descriptively. Mean and standard deviation were calcu-
lated for continuous variables, and numbers and percentages were calculated for
binary or categorical variables. T-test and Chi-square test were used to calculate
the p-values. RESULTS: Among all women in the registry (mean BMI: 29), 16%
(N443) were menopausal. Of this subset, 53.5% (N237) were treated with hor-
mone therapy. Hormone therapies included estrogen and progesterone combined
(58.67%), estrogen only (35.11%), soy/herbal remedies (4%), and raloxifene (2.22%).
For women with at least one menopausal symptom (N349), the most common
were hot flashes (59.60%) and vaginal dryness (59.60%). Non-menopausal women
were more likely to have hot flashes (66.67% vs. 49.76%, p-value0.007), mood
swings (56.06% vs. 25.12%, p-value0.001) and memory loss (55.30% vs. 39.23%,
p-value0.001) than menopausal women, which indicates that the menopause
diagnosis may be underestimated. This is consistent with the common issue found
in claims data, that menopausal women are not always diagnosed by physicians.
CONCLUSIONS: Women not diagnosed with menopause frequently had more
menopausal symptoms than women with diagnosed menopause. This may indi-
cate the underestimation of diagnosis. Therefore, it would be beneficial to use
menopausal symptoms as proxies to the diagnosis and control for them in the
research model. Techniques such as probabilistic linkage, could bridge the gap
between information in claims and registry data.
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Dequen P1, Kelly S2, Abrams K1
1University of Leicester, Leicester, UK, 2Pfizer Limited, Surrey, UK
In 2010, NICE published a clinical guideline on reducing the risk of venous throm-
boembolism (VTE) in patients admitted to hospital. At the time, five pharmological
VTE prophylaxis were recommended following elective knee or hip replacement
surgery—dabigatran etexilate, fondaparinux sodium, low molecular weight hepa-
rin (LMWH), rivaroxaban, and unfractionated heparin (UFH) for patients with renal
failure—in 2011, apixaban was also recommended for the same indication in the
UK. Although apixaban, dabigatran, and rivaroxaban were all assessed at different
times by NICE, each technology appraisal used a distinct methodology to compare
relevant interventions, directly and indirectly.OBJECTIVES:To evaluate the impact
of study identification methods and network size on indirect and mixed treatment
comparisons of pharmacological interventions for the prevention of VTE in pa-
tients undergoing elective orthopaedic surgery.METHODS:Data identification and
synthesis methods used in the NICE TA157, TA170, and TA245 were reviewed and
compared to best practice searching strategies and network meta-analysis meth-
odology. Literature searches specifically designed to collect data for use in network
meta-analysis were conducted and compared to original search results. Various
network sizes were tested to synthesise available evidence using Winbugs.
PRELIMINARY. RESULTS: Specifically designed search strategies to inform the ev-
idence base for network meta-analysis led to increased numbers of studies identi-
fied and included for synthesis increasing the total number of indirect comparisons
between existing VTE interventions. The impact of additional comparisons on rel-
ative treatment estimates was limited and precision did not increase.
CONCLUSIONS: Using a specific search strategy designed to optimise the identifi-
cation of studies for network meta-analysis allowed us to extend the network of
relevant studies; however, extending the network increased uncertainty in the
results and led to inconsistencies in the direct and indirect comparisons.
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OBJECTIVES: Countless studies have demonstrated that many emergency-room
visits and hospital admissions are drug-related and that a significant proportion of
these drug-related visits (DRV) are preventable. It has not been previously studied
which DRVs could be prevented through enhanced monitoring of therapy. The
objective of the study was to determine the incidence of DRVs attributed to labo-
ratory or physiologic abnormalities. METHODS: Three authors independently per-
formed comprehensive searches in relevant health care databases using pre-de-
termined search terms. Articles discussing DRV associated with poisoning,
substance abuse, or studied among existing in-patient populations were excluded.
Study country, year, sample, design, duration, DRV identification method, propor-
tion of DRVs associated with laboratory or physiologic abnormalities and associ-
ated medications were extracted. The three authors independently assessed se-
lected relevant articles according to the Strengthening the reporting of
observational studies in epidemiology (STROBE) and Consolidted Standards of Re-
porting Trials (CONSORT) guides as applicable according to the studies’
methodology. RESULTS: The initial literature search yielded a total of 1,780 articles
of which 43 articles meeting inclusion criteria and reporting sufficient laboratory or
physiologic data were included in the overall analysis. Half (52%) employed pro-
spective methodologies, which included both chart review and patient interview;
however, the overwhelming majorityof identified studies assessed only adverse
drug reactions (ADR) as a drug-related cause for DRV. Among the 43 studies, re-
ported DRV ranged between 0.4% and 40.9%, of which an association with labora-
tory or physiologic abnormalities represented 0.8% - 69.7% of cases. Most labora-
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tory-associated DRVs could be linked to immunosuppressant, antineoplastic,
anticoagulant and diabetes therapy, while physiologic-associated DRVs were at-
tributed to cardiovascular therapies and NSAIDS. CONCLUSIONS: Significant pro-
portions of laboratory and physiologic abnormalities contribute to DRVs and are
consistently linked to specific drugs. These therapies could be potential targets for
enhanced medication monitoring initiatives to proactively avert potential DRVs.
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OBJECTIVES: Unintentional exposures to potent opioid medications by young chil-
dren can cause severe illness or death. An oral film formulation of buprenorphine/
naloxone was introduced in the United States (US) in September 2010. The
RADARS®System Poison Center program collects data about exposure to opioid
medications, including patient age, reason for exposure, specific formulation, and
medical outcome; in 2011Q4, 48/57 US poison centers provided data. We sought to
determine unintentional exposure rates and associated medical outcomes for bu-
prenorphine/naloxone tablets and oral film among children less than 6 years old.
METHODS: RADARS System Poison Center program case counts and medical out-
comes for unintentional exposures to buprenorphine/naloxone tablets and oral
film among children aged 0 – 5 years from October 1, 2010 – December 31, 2011 were
analyzed. To account for drug availability in the community, rates were standard-
ized using unique recipients of a dispensed drug (URDD) per year-quarter. Negative
binomial regression was used to estimate rates and confidence intervals.RESULTS:
Exposures to buprenorphine/naloxone tablets (average 0.68 cases/1,000 URDD; 95%
CI: 0.64 – 0.73) were more common than exposures to oral film (average 0.08 cases/
1,000 URDD; 95% CI: 0.07 – 0.10; rate ratio 8.1; 95% CI: 6.5 – 10.0; p  0.0001). Major
medical outcomes or death were reported in 0/92 (0%) oral film exposures and
19/869 (2.2%) tablet exposures (p0.24). CONCLUSIONS: Among children aged 0 – 5
years, unintentional exposures to buprenorphine/naloxone oral film are less fre-
quent than exposures to buprenorphine/naloxone tablets after adjustment for
drug availability. Major medical outcomes and death were uncommon with either
formulation and there were no deaths involving buprenorphine/naloxone oral film.
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PROGRAM IN TURKEY
Kockaya G1, Atikeler K2, Tuna E3
1Health Economics and Policy Association, Ankara, Turkey, 2Ankara University, Ankara, Turkey,
3Hacettepe University, Ankara, Turkey
OBJECTIVES: Rotavirus is the one of important disease for Turkey. It was reported
that 500.000 child admitted to hospitals due Rotavirus in Turkey per year. Total cost
of Rotavirus to Turkish economy was reported as US$ 40 million per year. The aim
of study is reflects the government perspective attributed to investing in Rotavirus
Vaccination(RV) in Turkey, and how changes in morbidity and mortality influence
government expenditure over many generations. METHODS: The model applies a
generational accounting approach for estimating the inter-temporal fiscal impact
of policy changes with accounting for direct fiscal transfers between age cohorts
and the State during different life stages while simultaneously accounting for ro-
tavirus medical costs, and how rotavirus mortality and morbidity influence gov-
ernment fiscal transfers. Costs are expressed in US $(1 US$ 1.75 TL). The model is
constructed using Turkish life tables, rotavirus related and unrelated health care
costs, employment earnings adjusted for age and social parameters. The model
compares vaccinated and unvaccinated cohorts against rotavirus using discounted
net tax revenues for different vaccine cost like US$ 36,24 and 12. RESULTS: Dis-
counted Net Tax Revenue(DNTR) between vaccinated and unvaccinated cohorts
for vaccine cost US$ 12 was US$ 84 and US $ 98 million for 25 and 50 years, respec-
tively. DNTR for vaccine cost US$ 24 and US$ 36 were US$ 19 and US$ 33 million,
US$ (-) 45 and US$ (-) 32 million, respectively. Investing in rotavirus vaccination
represented return for government at year 25 and 50 for vaccine cost US$ 12 and
US$ 24. Vaccine cost US$ 36 didn‘t represent return for government.
CONCLUSIONS: Long-term government net tax revenues were sensitive to vaccine
prices, therefore it is an important determinant of economic value of the vaccine.
Investments in RV prevention could also deliver early cost-offsets related to the
reduced health care expenditure in Turkey.
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OBJECTIVES: By means of «Budget impact analysis» define what type of surgical
gowns and drapes: disposable or reusable, is more rational to apply in surgery.
METHODS: Budget impact analysis was provided. The study estimated direct costs:
expenses for reusable and disposable gowns and drapes usage, drug therapy and
late complications (peritonitis, sepsis, phlegmon and abscess) treatment. Effective-
ness data was taken from 2 clinical trials: «Moylan J.A., Fitzpatrick K.T., Davenport
K.E. Reducing wound infections. Improved gown and drape barrier perfomance.
Arch Surg. – 1987» and «Surgical site infection by surgical category and type of
incision - 5 years from July 2004 to June 2009, England». Risk of postoperative
complications development was the main effectiveness criterion. Two types of
surgical linen were compared: simple surgical sheet, as an example of reusable
surgical linen, and a set of disposable gowns ad drapes. RESULTS: It was estab-
lished that the use of disposable surgical linen provides more effectiveness in
comparison with reusable analogs. Calculation of total expenses for use of 2 com-
pared alternatives showed that use of disposable surgical linen is economically
more favorable (285,4 $ for 1 operation carrying out) in comparison with the appli-
cation of reusable surgical analogs (603,6 $). Transition to this alternative scheme
of medical care allows to buy additional number of surgical sets (1 673 sets during
one year), on the money saved as a result of this transition. Unifactor sensivity
analysis was carried out, which showed that results of our pharmacoeconomic
study were stable. CONCLUSIONS: Total costs of disposable surgical linen usage
(428 100 $ for 1 500 operation carrying out during 1 year) appeared to be much less,
than those of reusable analogs application (905 400 $). That is why disposable
gowns and drapes can be recommended as economic.
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OBJECTIVES: Apply probabilistic linkage to add menopause symptoms recorded in
a registry database to claims data, and compare health care utilizations and costs
among women with and without symptoms. METHODS: Menopausal women age
45 prescribed estrogen only hormone therapy from a large U.S. claims database
(04/01/2005-09/30/2008) were linked with the University of Michigan Women’s Reg-
istry Database menopausal group using probabilistic linkage, controlling for osteo-
porosis, gynecological disorders/procedures, genital infection, bladder/pelvic floor
support problem, gynecology system cancer, breast condition, gut condition, hor-
mone disorder, nerve problem, and other comorbidities (rheumatoid disease, de-
pression, blood clotting). After linkage, registry patients’ menopause symptoms
were added to claims database records. The same linkage procedures were re-
peated 250 times, the mean and 95% confidence interval (CI) of health care costs
and utilizations during the follow-up period were compared between women with
and without symptoms. RESULTS: Among 80 matched patients, 84% had at least
one symptom, with hot flashes being the most common. The average cost of pa-
tients with at least one symptom was much higher than of patients without symp-
toms ($13,570 [95% CI: $13,459-$13,680] vs. $3,391 [95% CI: $3,345-$3,436],
p-value0.001). Cost differences were mainly from inpatient ($1,997 [95% CI:
$1,925-$2,070], p-value0.001 vs. $247 [95% CI: $239-$254, p-value0.001), physi-
cian visit ($967 [95% CI: $961-$974], p-value0.001 vs. $248 [95% CI: $246- $251],
p-value0.001), and pharmacy costs ($3,676 [95% CI: $3,648-$3,704], p-value0.001
vs. $903 [95% CI: $890- $916], p-value0.001). Women with symptoms were more
likely to have inpatient (12.78% vs. 4.05%, P0.001), outpatient emergency room
(20.6% vs. 6.31%, p0.001), and physician visits (79.86% vs. 18.71%, p0.001).
CONCLUSIONS: Women with menopause symptoms incur higher health care uti-
lizations and costs than those without. Results suggest that symptoms can be an
important predictor of economic outcomes. Therefore, it would be beneficial to
control for them using probabilistic linkage to bridge the gap between registry and
claims data.
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OBJECTIVES: To evaluates and compares the cost effectiveness of 2mg dienogest
versus gonadotropin-releasing hormone analogs (GnRH-a) for endometriosis treat-
ment. Some treatments only eliminate endometriosis symptoms while others
shrink and reduce lesions in addition to symptom treatment. In this context, di-
enogest was compared to the class of GnRH analogs, which are used in Turkey for
both symptomatic treatment and as a contributor to shrinkage/reduction of the
endometriotic lesions.METHODS: The population consisted of women age 18 to 49
eligible for GnRH-a treatment. GnRH-a treatment included leuprolide acetate (3
months intramuscular / subcutaneous injection 11.25mg, 1 syringe/box) and goserelin
acetate implant (3.6 mg 1 syringe/box). A Markov model was used to simulate three health
outcomes: treatment response, unresponsive to treatment and death. Costs were
assessed and compared between the 2mg dienogest group versus the selected
GnRH-a group over a 2-year time period. Clinical endpoints were quality adjusted
life years (QALY) and mean response time (50% improvement in Visual Analog
Scale[VAS] pain score) in health status when a patient responded to treatment.
Model output was calculated as incremental cost per QALY and per respondent
years gained. RESULTS: A 2-year model was utilized for GnRH-a therapy and sup-
porting treatment, and a 1-year model for treatment without supportive therapy.
Study results showed that dienogest had the same efficiency but lower health care
costs according to incremental cost per QALY and per respondent years gained for
both the 1 and 2-year models. Sensitivity analysis for treatment response and
regression rate also showed that 2mg dienogest was a more cost-effective treat-
ment option than GnRH-a agents. CONCLUSIONS: Results demonstrate that 2mg
dienogest is a more cost-effective option to treat endometriosis compared with
both GnRH-a agents. This result may assist with reimbursement plan selection for
endometriosis treatment from payers’ perspectives.
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